The purpose of this study is to optimize the complex treatment of non-ischemic dilated cardiomyopathy by supplementing the standard drug therapy with intracoronary administration of umbilical cord-derived mesenchymal stromal cells.~Sixty patients will be selected and randomly divided into the main and control groups in a 1: 1 ratio.~Patients of the main group will receive complex treatment based on the addition to the standard drug therapy of intracoronary administration of 10 million mesenchymal stromal cells of the umbilical cord, and patients of the control group will receive only standard drug therapy.~Every patient will maintain their standard treatment of chronic heart failure, with maximum tolerated dosage without side effects.~The day of infusion will be considered day zero. From that moment, followup will be divided into 0-1,1-3 and 3-6 months.~Clinical results will be analyzed after completion of 6 months of followup.
The purpose of this study is to optimize the complex treatment of chronic heart failure of non-ischemic etiology by supplementing umbilical cord mesenchymal stem cells to the standard drug therapy.